Natriuretic peptides in heart failure: Where we are, where we are going

Internal and Emergency Medicine

Volumn 6, Issue 1, 2011, Pages 63-68

  Palazzuoli, Alberto ^a   Antonelli, Giovanni ^a   Quatrini, Ilaria ^a   Nuti, Ranuccio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

B Type natriuretic peptide; Coronary artery disease; Heart failure; NT pro BNP

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR;

BLOOD; CORONARY ARTERY DISEASE; HEART FAILURE; HUMAN; METABOLISM; REVIEW;

BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES;

EID: 79551588582     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-010-0438-x     Document Type: Review

References (29)

1. European Society of Cardiology, Heart Failure Association of the ESC (HFA), European Society of Intensive Care Medicine (ESICM), Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Tendera M, Auricchio A, Bax J, Böhm M, Corrà U, della Bella P, Elliott PM, Follath F, Gheorghiade M, Hasin Y, Hernborg A, Jaarsma T, Komajda M, Kornowski R, Piepoli M, Prendergast B, Tavazzi L, Vachiery JL, Verheugt FW, Zamorano JL, Zannad F (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10(10): 933-989.
2. Fonarow GC, Peacock WF, Phillips CO, et al., ADHERE Scientific Advisory Committee and Investigators (2007) Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 49(19): 1943-1950.
3. Parrinello G, Torres D, Paterna S, Licata G (2009) Is there any novelty on the horizon of heart failure management in internal medicine? The evaluation of body fluid accumulation. Intern Emerg Med 4: 269-270.
4. Hirayama A, Kusuoka H, Yamamoto H, Sakata Y, Asakura M, Higuchi Y, Mizuno H, Kashiwase K, Ueda Y, Okuyama Y, Hori M, Kodama K (2005) Serial changes in plasma brain natriuretic peptide concentration at the infarct and non-infarct sites in patients with left ventricular remodelling after myocardial infarction. Heart 91(12): 1573-1577.
5. Silver MA, Maisel A, Yancy CW, McCullough PA, Burnett JC Jr, Francis GS, Mehra MR, Peacock WF 4th, Fonarow G, Gibler WB, Morrow DA, Hollander J, BNP Consensus Panel (2004) A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 10(5 Suppl 3): 1-30.
6. De Lemos JA, McGuire DK, Khera A, Das SR, Murphy SA, Omland T, Drazner MH (2009) Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. Am Heart J 157(4): 746-753.
7. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A (2002) Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 16; 39(2): 202-209.
8. Dentali F, Donadini M, Gianni M, Bertolini A, Lonn E, Venco A, Cattozzo G, Ageno W (2009) Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. Intern Emerg Med 4: 123-128.
9. Maisel AS, Krishnaswamy P, Nowak RM et al (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347: 161-167.
10. Troughton RW, Prior DL, Pereira JJ, Martin M, Fogarty A, Morehead A, Yandle TG, Richards AM, Starling RC, Young JB, Thomas JD, Klein AL (2004) Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 43: 416-422.
11. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM (2001) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355(9210): 1126-1130.
12. Tschope C, Kasner M, Westermann D, Gaub R, Poller WC, Schultheiss HP (2005) The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 26: 2277-2284.
13. Dong SJ, de las Fuentes L, Brown AL, Waggoner AD, Ewald GA, Davila-Roman VG (2006) N-terminal pro B-type natriuretic peptide levels: correlation with echocardiographically determined left ventricular diastolic function in an ambulatory cohort. J Am Soc Echocardiogr 19: 1017-1025.
14. Lim TK, Ashrafian H, Dwivedi G, Collinson PO, Senior R (2006) Increased left atrial volume index is an independent predictor of raised serum natriuretic peptide in patients with suspected heart failure but normal left ventricular ejection fraction: implication for diagnosis of diastolic heart failure. Eur J Heart Fail 8: 38-45.
15. Kirk V, Bay M, Parner J, Krogsgaard K, Herzog TM, Boesgaard S, Hassager C, Nielsen OW, Aldershvile J, Nielsen H (2004) N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail 6: 335-341.
16. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G et al (2000) The TIMI risk score for unstable angina/non ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 284: 835-842.
17. Palazzuoli A, Gennari L, Calabria P, Quatrini I, Vecchiato L, De Paola V et al (2005) Relation of plasma brain natriuretic peptide levels in non-ST-elevation coronary disease and preserved systolic function to number of narrowed coronary arteries. Am J Cardiol 96: 1705-1710.
18. Morrow DA, Braunwald E (2003) Future of biomarkers in acute coronary syndromes moving toward multimarker strategy. Circulation 108: 250-252.
19. Ezekowitz JA, Théroux P, Chang W, Mahaffey KW, Granger CB, Weaver WD, Hochman JS, Armstrong PW (2006) N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. Can J Cardiol 22: 393-397.
20. Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, Hlavin P, Maisel A (2002) B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 39: 131-138.
21. Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A (2004) N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110: 2168-2174.
22. Aspromonte N, Valle R, Peacock WF, Vanderheyden M, Maisel A (2008) Inpatient monitoring and prognostic importance of B-type natriuretic peptide. Congest heart Fail 14: 30-34.
23. Donadini MP, Squizzato A, Dentali F, Ageno W (2009) Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable? Intern Emerg Med 4: 123-128.
24. Palazzuoli A, Deckers J, Calabrò A, Campagna MS, Nuti R, Pastorelli M, Pasqui AL, Bruni F, Auteri A, Puccetti L (2006) Brain natriuretic peptide and other risk markers for outcome assessment in patients with non-ST-elevation coronary syndromes and preserved systolic function. Am J Card 98: 1322-1328.
25. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, Frampton C, Yandle TG, Australia-New Zealand Heart Failure Group (2006) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 37: 1781-1787.
26. Cohn N, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675.
27. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missov ED, Clerico A, Tognoni G, Cohn JN (2006) Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 52: 1528-1538.
28. Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T (2009) Evaluation of novel biomarkers for the diagnosis of acute destabilized heart failure in shortness-of-breath patients. Heart 95(18): 1508-1513.
29. Voors AA, von Haehling S, Anker SD et al (2009) C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 30: 1187-1194.